Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.78 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.73 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014370 | 1.00 | S1PR1 (0.78) | S1PR1S1PR4S1PR5ADORA3CYP2C9 | |
| SCHEMBL2022280 | 1.00 | S1PR1 (0.78) | S1PR1S1PR4S1PR5ADORA3CYP2C9 | |
| SCHEMBL17690534 | 0.91 | S1PR1 (0.72) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2017713 | 0.91 | S1PR1 (0.72) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2018192 | 0.91 | S1PR1 (0.72) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2022530 | 0.91 | S1PR1 (0.72) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2019091 | 0.91 | S1PR1 (0.71) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2015894 | 0.91 | S1PR1 (0.71) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2023095 | 0.91 | S1PR1 (0.71) | S1PR1S1PR4S1PR5ADORA3S1PR2 | |
| SCHEMBL2017157 | 0.91 | S1PR1 (0.71) | S1PR1S1PR4S1PR5ADORA3S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105816453-B | Substituted tricyclic acid derivatives as S1P1 receptor agonists for the treatment of autoimmune and inflammatory disorders | 艾尼纳制药公司 | 2021-03-05 | — | — | CN | disclosed |
| EP-2342205-B1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9108969-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20130184307-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8415484-B2 | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2342205-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals ,Inc. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010027431-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336966-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR4 5/4885S1PR5 2/4885 |
| US-20110160243-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR4 5/4885S1PR5 2/4885 |
| US-20130184307-A1 | SUBSTITUTED TRICYCLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR4 5/4885S1PR5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.